INDV Indivior Pharmaceuticals (INDV) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001625297
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
206
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed
What the filings say about INDV
Insiders, 180 days
-$2.7M net sold
1 buyer · 2 sellers · 0% of sales under a 10b5-1 plan
Indivior Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Indivior Pharmaceuticals, Inc. insiders sold a net $2.7M of stock across 13 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 5, 2026.
- The trade is 5.4% of the 27,638 shares held after it.
- No other insider bought within 30 days.
- 206 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Anderson Woodrow D bought about $53.5K of INDV on Aug 27, 2026; 206 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.7% of the 26,138 shares held after it.
- No other insider bought within 30 days.
- 206 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Anderson Woodrow D bought about $54.4K of INDV on Aug 5, 2026; 206 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 11, 2026.
- The trade is 8.9% of the 209,337 shares held after it.
- No other insider sold within 30 days.
- 206 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Heidbreder Christian sold about $764.6K of INDV on Jul 10, 2026; 206 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 8.2% of the 227,923 shares held after it.
- 1 other insider sold within 30 days.
- 206 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Heidbreder Christian sold about $707.4K of INDV on Jun 11, 2026; 1 other insider sold within 30 days and 206 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 12.6% of the 284,751 shares held after it.
- 1 other insider sold within 30 days.
- 206 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Preblick Ryan sold about $1.4M of INDV on Jun 8, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 206 funds added in the latest 13F quarter.13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$2.7M over 180 days
+$108.0K over 90 days
below 73% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
206 funds bought in last quarter
more than 91% of Pharma & Biotech
Revenue
+4.3% year over year
more than 51% of Pharma & Biotech
Margin
16.9% net margin
more than 86% of Pharma & Biotech
Buybacks
$302.0M repurchased, FY to 2026-06-30
more than 82% of Pharma & Biotech
Short interest
9.5% of the float short (float per yahoo 2026-10-26) · 5.3 days to cover · settled 2026-09-30
more than 67% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch INDV
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+36.7%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns INDV: institutional holders (13F)
13F holdings, latest reported quarter
18,709,432 sh
$767.6M
7,572,287 sh
$310.7M
6,127,212 sh
$251.4M
5,495,486 sh
$225.5M
4,992,071 sh
$204.8M
Congress trades in INDV
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
INDV planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Heidbreder Christian
Filed 2026-07-10
$764.6K
INDV mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
CapForce IBD 50 ETF
$2.4M position · as of 2026-07-31
3.0%
Invesco S&P SmallCap Health Care ETF
$3.2M position · as of 2026-05-31
2.4%
Invesco S&P SmallCap Momentum ETF
$66.6M position · as of 2026-07-31
2.2%
Virtus NFJ Small-Cap Value Fund
$5.2M position · as of 2026-06-30
2.0%
Invesco Russell 2000 Dynamic Multifactor ETF
$5.1M position · as of 2026-05-31
1.8%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$7.0M position · as of 2026-06-30
1.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $2.7M sold by insiders over 180 days, 206 funds added last quarter. Each figure is a federal filing, dated the day it went public.
INDV financials
Revenue growth
+4.3%
XBRL, annual
Net margin
16.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.3B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM INDV
| FY Dec 2025 | $1.2B |
| FY Dec 2024 | $1.2B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $343.0M |
| Mar 2026 | $317.0M |
| Dec 2025 | $358.0M |
| Sep 2025 | $314.0M |
| Jun 2025 | $302.0M |
| Mar 2025 | $266.0M |
| Dec 2024 | $299.0M |
| Sep 2024 | $307.0M |
At each fiscal year end
Single quarter
Net margin, TTM
+26.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM INDV
| FY Dec 2025 | +16.9% |
| FY Dec 2024 | +0.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +35.6% |
| Mar 2026 | +28.1% |
| Dec 2025 | +28.5% |
| Sep 2025 | +13.4% |
| Jun 2025 | +6.0% |
| Mar 2025 | +17.7% |
| Dec 2024 | +7.0% |
| Sep 2024 | +7.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$111.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM INDV
| FY Dec 2025 | -$93.0M |
| FY Dec 2024 | $7.0M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $222.0M |
| Mar 2026 | -$29.0M |
| Dec 2025 | -$245.0M |
| Sep 2025 | -$59.0M |
| Jun 2025 | $141.0M |
| Mar 2025 | $70.0M |
| Dec 2024 | -$33.0M |
| Sep 2024 | -$5.0M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity INDV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.08x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt INDV
| FY Dec 2025 | -0.08x |
| FY Dec 2024 | 0.11x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.08x |
| Mar 2026 | -0.23x |
| Dec 2025 | -0.08x |
| Sep 2025 | 0.55x |
| Jun 2025 | 0.67x |
| Mar 2025 | 0.45x |
| Dec 2024 | 0.11x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity INDV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+26.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets INDV
| FY Dec 2025 | +16.6% |
| FY Dec 2024 | +0.5% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +26.4% |
| Mar 2026 | +19.5% |
| Dec 2025 | +16.6% |
| Sep 2025 | +9.0% |
| Jun 2025 | +7.4% |
| Mar 2025 | -0.5% |
| Dec 2024 | +0.5% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
invested capital is zero or negative
Return on invested capital INDV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+110.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed INDV
| FY Dec 2025 | +77.2% |
| FY Dec 2024 | +8.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +110.6% |
| Mar 2026 | +84.5% |
| Dec 2025 | +77.2% |
| Sep 2025 | +50.3% |
| Jun 2025 | +55.3% |
| Mar 2025 | +7.8% |
| Dec 2024 | +8.7% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
12.39x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing INDV
| FY Dec 2025 | 21.88x |
| FY Dec 2024 | 248.60x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 14.71x |
| Mar 2026 | 15.63x |
| Dec 2025 | 21.88x |
| Sep 2025 | 23.87x |
| Jun 2025 | 17.55x |
| Mar 2025 | n/a |
| Dec 2024 | 248.60x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$4.3B
market value at close 2026-10-26 on 2026-07-28 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value INDV
| FY Dec 2025 | $4.6B |
| FY Dec 2024 | $1.7B |
| FY Dec 2023 | $2.0B |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $5.3B |
| Mar 2026 | $4.1B |
| Dec 2025 | $4.6B |
| Sep 2025 | $2.9B |
| Jun 2025 | $1.7B |
| Mar 2025 | $1.1B |
| Dec 2024 | $1.7B |
| Sep 2024 | $1.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-2.7%
TTM free cash flow over market value at close 2026-10-26
FCF yield INDV
| FY Dec 2025 | -2.1% |
| FY Dec 2024 | +0.4% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -2.2% |
| Mar 2026 | -5.0% |
| Dec 2025 | -2.1% |
| Sep 2025 | +4.0% |
| Jun 2025 | +9.4% |
| Mar 2025 | +9.8% |
| Dec 2024 | +0.4% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.05x
P/E over trailing EPS growth of 232%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing INDV
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.06x |
| Mar 2026 | n/a |
| Dec 2025 | 0.01x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.1B | $901.0M |
| Gross profit | $994.0M | $957.0M | $919.0M | $749.0M |
| Operating income | $262.0M | $38.0M | -$152.0M | -$77.0M |
| Net income | $210.0M | $7.0M | -$126.0M | -$42.0M |
| EPS (diluted) | 1.64 | 0.05 | -0.92 | -0.30 |
| Operating cash flow | -$27.0M | $36.0M | -$300.0M | -$4.0M |
| Cash | $195.0M | $319.0M | $316.0M | n/a |
| Long-term debt | $290.0M | $315.0M | $237.0M | n/a |
| Buybacks | $11.0M | $173.0M | $33.0M | $90.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
INDV Stock Sonar score 6/7 axes
Find similar shapesCompareINDV ranks highest on profitability (97th percentile) and institutional and government (91st), and lowest on risk and compliance (28th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
INDV filings, in plain words
Are Indivior Pharmaceuticals insiders buying or selling INDV?
In the 180 days to 2026-10-28, Indivior Pharmaceuticals insiders were net sellers, a net $2.7M: $108.0K of purchases and $2.8M of sales reported on Form 4, by 1 buyer and 2 sellers.
Read the full summary
In the 180 days to 2026-10-28, Indivior Pharmaceuticals insiders were net sellers of INDV, a net $2.7M across purchases and sales reported on Form 4 by 1 buyer and 2 sellers. Sales outweighed purchases more than tenfold by value. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
